Dyslipidemia in Patients with Chronic and End-stage Kidney Disease

Overview

Journal Cardiorenal Med

Publisher Karger

Specialties Cardiology & Vascular Diseases
Endocrinology
Nephrology

Date 2014 Jan 24

PMID 24454313

Citations 13

Authors

Jad Omran

Ashraf Al-Dadah

Kevin C Dellsperger

Affiliations

Soon will be listed here.

Abstract

In this review, we discuss the physiology, diagnosis and treatment of dyslipidemia in patients with chronic and end-stage renal disease. The recent important clinical trials in patients with chronic kidney disease and dyslipidemia are reviewed. Because of the lack of evidence in treating lipid abnormalities in this specific patient population, we propose that future studies should focus on the pathophysiological mechanisms and treatment of dyslipidemia in this special patient population.

Citing Articles

Butyrate-Mediated Modulation of Paraoxonase-1 Alleviates Cardiorenometabolic Abnormalities in a Rat Model of Polycystic Ovarian Syndrome.

Olaniyi K, Areloegbe S, Badejogbin O, Ajadi I, Ajadi M Cardiovasc Drugs Ther. 2024; .

PMID: 39549177 DOI: 10.1007/s10557-024-07649-y.

Does metabolic syndrome increase contrast-induced nephropathy in patients with normal renal function?.

Shemirani H, Hosseini A J Res Med Sci. 2024; 29:5.

PMID: 38524741 PMC: 10956558. DOI: 10.4103/jrms.jrms_136_21.

Novel oxidized LDL-based clinical markers in peritoneal dialysis patients for atherosclerosis risk assessment.

Papadea P, Kalaitzopoulou E, Skipitari M, Varemmenou A, Papasotiriou M, Papachristou E Redox Biol. 2023; 64:102762.

PMID: 37302344 PMC: 10363433. DOI: 10.1016/j.redox.2023.102762.

Lipid status association with 25-hydroxy vitamin D: Cross sectional study of end stage renal disease patients.

Milinkovic N, Saric M, Jovicic S, Mirkovic D, Lezaic V, Ignjatovic S J Med Biochem. 2020; 39(3):309-317.

PMID: 33269019 PMC: 7682808. DOI: 10.2478/jomb-2019-0032.

Dyslipidemia and Intraperitoneal Inflammation Axis in Peritoneal Dialysis Patients: A Cross-Sectional Pilot Study.

Stepanova N, Driianska V, Savchenko S Kidney Dis (Basel). 2020; 6(1):35-42.

PMID: 32021872 PMC: 6995979. DOI: 10.1159/000503632.

References

Go A, Chertow G, Fan D, McCulloch C, Hsu C . Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351(13):1296-305. DOI: 10.1056/NEJMoa041031. View

Lowrie E, Lew N . Commonly measured laboratory variables in hemodialysis patients: relationships among them and to death risk. Semin Nephrol. 1992; 12(3):276-83. View

BRADFORD R, SHEAR C, CHREMOS A, Dujovne C, Downton M, FRANKLIN F . Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med. 1991; 151(1):43-9. DOI: 10.1001/archinte.151.1.43. View

. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002; 288(23):2998-3007. DOI: 10.1001/jama.288.23.2998. View

Kagan A, BAR-KHAYIM Y, Schafer Z, Fainaru M . Kinetics of peritoneal protein loss during CAPD: II. Lipoprotein leakage and its impact on plasma lipid levels. Kidney Int. 1990; 37(3):980-90. DOI: 10.1038/ki.1990.74. View

. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984; 251(3):351-64. DOI: 10.1001/jama.1984.03340270029025. View

Foley R, Parfrey P, Sarnak M . Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998; 32(5 Suppl 3):S112-9. DOI: 10.1053/ajkd.1998.v32.pm9820470. View

. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143-421. View

Shoji T, Fukumoto M, Kimoto E, Shinohara K, Emoto M, Tahara H . Antibody to oxidized low-density lipoprotein and cardiovascular mortality in end-stage renal disease. Kidney Int. 2002; 62(6):2230-7. DOI: 10.1046/j.1523-1755.2002.00692.x. View

10.

Ziouzenkova O, Asatryan L, Akmal M, Tetta C, Wratten M, Jurgens G . Oxidative cross-linking of ApoB100 and hemoglobin results in low density lipoprotein modification in blood. Relevance to atherogenesis caused by hemodialysis. J Biol Chem. 1999; 274(27):18916-24. DOI: 10.1074/jbc.274.27.18916. View

11.

Wanner C, Krane V, Marz W, Olschewski M, Mann J, Ruf G . Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005; 353(3):238-48. DOI: 10.1056/NEJMoa043545. View

12.

Massy Z, Kim Y, Guijarro C, Kasiske B, Keane W, ODonnell M . Low-density lipoprotein-induced expression of interleukin-6, a marker of human mesangial cell inflammation: effects of oxidation and modulation by lovastatin. Biochem Biophys Res Commun. 2000; 267(2):536-40. DOI: 10.1006/bbrc.1999.1992. View

13.

. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998; 339(19):1349-57. DOI: 10.1056/NEJM199811053391902. View

14.

Shoji T, Nishizawa Y, Fukumoto M, Shimamura K, Kimura J, Kanda H . Inverse relationship between circulating oxidized low density lipoprotein (oxLDL) and anti-oxLDL antibody levels in healthy subjects. Atherosclerosis. 1999; 148(1):171-7. DOI: 10.1016/s0021-9150(99)00218-x. View

15.

Shoji T, Kimoto E, Shinohara K, Emoto M, Ishimura E, Miki T . The association of antibodies against oxidized low-density lipoprotein with atherosclerosis in hemodialysis patients. Kidney Int Suppl. 2003; (84):S128-30. DOI: 10.1046/j.1523-1755.63.s84.37.x. View

16.

Fellstrom B, Jardine A, Schmieder R, Holdaas H, Bannister K, Beutler J . Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009; 360(14):1395-407. DOI: 10.1056/NEJMoa0810177. View

17.

Guyton J, Blazing M, Hagar J, Kashyap M, Knopp R, McKenney J . Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. Arch Intern Med. 2000; 160(8):1177-84. DOI: 10.1001/archinte.160.8.1177. View

18.

Lobo J, Santos F, Grosso D, Lima R, Barreira A, Leite Jr M . Electronegative LDL and lipid abnormalities in patients undergoing hemodialysis and peritoneal dialysis. Nephron Clin Pract. 2008; 108(4):c298-304. DOI: 10.1159/000127982. View

19.

Coresh J, Astor B, Greene T, Eknoyan G, Levey A . Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2002; 41(1):1-12. DOI: 10.1053/ajkd.2003.50007. View

20.

Abela G, Vedre A, Janoudi A, Huang R, Durga S, Tamhane U . Effect of statins on cholesterol crystallization and atherosclerotic plaque stabilization. Am J Cardiol. 2011; 107(12):1710-7. DOI: 10.1016/j.amjcard.2011.02.336. View